Superstring Capital Management established a new $5.82 million position in Vir Biotechnology by acquiring 730,548 shares in Q1 2026. The investment appears to be a bet on upcoming clinical catalysts rather than current financials, with Vir expecting Phase 3 hepatitis delta data in Q4 2026 and pivotal Phase 3 oncology trials in 2027. Despite being unprofitable, the company has a strong balance sheet with $809.3 million in cash and runway into late 2028.

Multiple large-cap stocks experienced significant declines last week due to earnings misses and disappointing guidance. The top losers included Rambus (down 28.47%), Summit Therapeutics (down 27.82%), and Teradyne (down 17.85%), with notable declines also from Roblox, Spotify, and Robinhood. Weak financial results and lowered forward guidance across tech, fintech, and other sectors shook investor confidence.

U.S. equities reached all-time highs on Friday as Apple's blowout Q2 earnings powered a broad technology rally. The S&P 500 advanced 0.7% to 7,262, while the Nasdaq 100 rose 1.1% to 27,743. Apple surged 5.1% on strong revenue and guidance, while software stocks like Atlassian, Twilio, and Reddit soared on earnings beats. Energy stocks declined as crude oil fell over 3%. Some mega-cap earnings disappointed, including Amgen and Roblox, which posted significant declines.

A wave of momentum swept through large-cap stocks during the week of April 13-17, 2026, with ten standout performers. Notable gainers include Avis Budget Group (71.48% jump driven by short squeeze), IonQ (62.86% surge following DARPA contract award), Oklo (33.35% rise on nuclear power narrative), Robinhood (33.22% gain from bullish analyst outlook and crypto rebound), and Strategy Inc (31.86% increase). Other top performers include Tempus AI, Credo Technology, Affirm Holdings, and Summit Therapeutics, with gains ranging from 28-31%.

U.S. equities reached all-time highs on Thursday as President Trump announced a 10-day ceasefire between Israeli and Lebanese leaders. The S&P 500 advanced to 7,038.57 (+0.2%), while the Nasdaq 100 rallied 0.6% to 26,359 on its 12th straight session of gains. Oil prices surged on Iran's Hormuz toll legislation, with WTI crude jumping 2.5% to $93.58. Energy and technology sectors led gains, though healthcare stocks declined following weak guidance from Abbott Laboratories.

Summit Therapeutics faces significant near-term risk as its FDA decision on ivonescimab is expected by November 14, 2026. The drug failed to demonstrate statistically significant overall survival improvement in non-Chinese patient populations, which the FDA requires for approval. Meanwhile, Axsome Therapeutics and Madrigal Pharmaceuticals are positioned to potentially outperform Summit by year-end, driven by upcoming catalysts and strong revenue growth.

The FDA has accepted Summit Therapeutics' Biologics License Application for ivonescimab in combination with chemotherapy for EGFR-mutated non-small cell lung cancer patients. The drug will undergo complete review with a PDUFA goal action date of November 14, 2026. Phase 3 trial data showed ivonescimab demonstrated improved overall survival compared to chemotherapy alone, and the company is expanding its clinical development program with additional Phase 3 studies.

Ten large-cap stocks experienced significant declines during the week of January 12-16, 2026. Regencell Bioscience led losses with a 42.08% drop, while Trip.com fell 20.19% following a Chinese anti-monopoly investigation. Other major decliners included Atlassian (19.82%), Figma (19.41%), HubSpot (16.56%), and Intuit (14.38%), with analyst downgrades cited for several stocks.

Alumis shares surged 94.53% following positive Phase 3 trial results for envudeucitinib, an oral TYK2 inhibitor for psoriasis that met primary and secondary endpoints. The company announced plans to raise $175 million in capital to support commercialization of the drug and its pipeline. The broader market rose modestly with the S&P 500 gaining 0.62% and Nasdaq up 0.65%.

Summit Therapeutics, a healthcare company with a $14 billion market cap, is banking on its promising cancer drug ivonescimab, which showed potential superiority to Keytruda in clinical trials. However, the stock remains risky due to ongoing global trials and uncertain FDA approval.

Wall Street analysts highlight three potential comeback stocks across different sectors: The Trade Desk, Summit Therapeutics, and Sprouts Farmers Market, each facing challenges but showing promising signs of recovery.

Summit Therapeutics reported positive Phase 3 trial results for ivonescimab in lung cancer treatment, showing a 40% reduced risk of progression or death compared to competitor therapy, and plans to submit a Biologics License Application in Q4 2025.